Sun Pharmaceutical Industries, a
n international specialty pharmaceutical company focused on chronic diseases, and Intrexon Corporation, a leader in synthetic biology, have formed a joint venture (JV) to develop controllable gene-based therapies for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide. Initial targets are dry age-related macular degeneration (AMD), glaucoma and retinitis pigmentosa.
http://www.epicresearch.co/
0731-664-2300
No comments:
Post a Comment